Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2017 by CTD Holdings, Inc.
Sponsor:
Information provided by (Responsible Party):
CTD Holdings, Inc.
ClinicalTrials.gov Identifier:
NCT02939547
First received: September 21, 2016
Last updated: March 28, 2017
Last verified: March 2017
  Purpose
This research study is being conducted to find out whether Trappsol® Cyclo™, an experimental treatment for people with Niemann Pick disease Type C (NPC-1) is safe at 2 different dose levels and what effects it has on people who have this condition. NPC-1 is caused by a defect in the protein which is important for the transport of fatty substances like cholesterol out of cells. Without this protein, fats build up in the cells ultimately leading to organ damage. The way in which this experimental treatment works is not fully understood but laboratory experiments have shown that it can potentially remove cholesterol build up from the cells in people who have NPC-1. Approximately 12 patients will be asked to take part in this research study for up to 20 weeks (w) in total (including screening. treatment and follow-up). Recruitment is expected to take 6- 9 months.Patients who take part will receive treatment by an intravenous infusion every two weeks. The study will look at what the body does to the drug as well as what the drug does to the body by taking and examining blood and urine samples. Samples of cerebrospinal fluid (CSF) will be taken by lumbar puncture during and following the first and subsequent treatment doses. Liver and skin biopsy specimens will be taken to assess filipin staining. Cholesterol metabolism will be investigated in liver samples and splenic and hepatic elasticity will be assessed by ultrasound..Patients will also have their hearing tested, be asked questions by their doctor as well completing questionnaires to help assess any changes in their condition during treatment.This study is being sponsored and funded by CTD holdings Inc. It is planned to be run in the USA,.

Condition Intervention Phase
Niemann-Pick Disease, Type C1
Drug: Hydroxypropyl-beta-cyclodextrin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Basic Science
Official Title: A Phase I Study to Evaluate the Single and Multiple-dose Pharmacokinetics of Intravenous Trappsol Cyclo (HP-Beta-CD) in Patients With Niemann-Pick Disease Type C (NPC-1) and the Effects of Dosing Upon Biomarkers of NPC Disease

Resource links provided by NLM:


Further study details as provided by CTD Holdings, Inc.:

Primary Outcome Measures:
  • Maximum Concentration ( C max) of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels [ Time Frame: Pre- infusion then 2 ,4,6,8,8.5,9,10,11 12,16 and 20 hours after the start of the infusions at 1&12 w ]
    To compare the C max of Trappsol following 2 different dose levels of intravenous Trappsol in patients with NPC-1 disease following single and multiple doses

  • Time to Maximum Concentration (T max) of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels [ Time Frame: Pre- infusion,2 ,4,6,8,8.5,9,10,11 12,16 and 20 hours after the start of the infusions at 1&12 w ]
    To compare the T max of Trappsol following 2 different dose levels of intravenous Trappsol in patients with NPC-1 disease following single and multiple doses

  • Volume of Distribution of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels [ Time Frame: Pre- infusion,2 ,4,6,8,8.5,9,10,11 12,16 and 20 hours after the start of the infusions at 1&12 w ]
    To compare the Volume of Distribution of Trappsol following 2 different dose levels of intravenous Trappsol in patients with NPC-1 disease following single and multiple doses

  • Elimination half-life (T1/2) of Trappsol in plasma from patients with Niemann-Pick disease Type C1 by measurement of plasma levels [ Time Frame: Pre- infusion,2 ,4,6,8,8.5,9,10,11 12,16 and 20 hours after the start of the infusions at 1&12 w ]
    To compare the T1/2 of Trappsol following 2 different doses.


Secondary Outcome Measures:
  • CSF levels of Trappsol [ Time Frame: Pre-infusion then 2,4,6,8,12 hours after the first infusion ( w1) and 8h after the start of the last infusion (W12) ]
    To evaluate HP-β-CD concentrations in CSF following 2 different dose levels of intravenous Trappsol in patients with NPC-1 disease following single and multiple doses

  • Potential blood biomarkers of NPC1 [ Time Frame: Screening, baseline,then at 2,4,8,12 and 14 weeks ]
    To investigate the effect of 2 different doses of intravenous Trappsol upon peripheral blood biomarkers of NPC-1 disease

  • Potential CSF biomarkers of NPC1 [ Time Frame: Baseline, then at 12 and 14 weeks ]
    To investigate the effect of 2 different doses of intravenous Trappsol upon biomarkers of NPC-1 disease in CSF

  • Serum cholesterol precursors and metabolites [ Time Frame: Screening, baseline the Days1,3,,5,8,11 and 15 after the first infusion of Trappsol then at d2,3,5,8,11and 15 after the last infusion ( W12) ]
    To investigate the effect of 2 different doses of intravenous Trappsol in patients with NPC-1 disease upon serum and lymphocytic markers of cholesterol metabolism

  • Fractionated cholesterol in hepatic tissue [ Time Frame: Baseline and 12 weeks ]
    To investigate the effect of 2 different doses of intravenous Trappsol in patients with NPC-1 disease upon fractionated cholesterol in hepatic tissue

  • Splenic morphology assessed by qualitative change in ultrasound compared with baseline, NIH total and individual domain severity scores [ Time Frame: Baseline then 14 weeks ]
    To evaluate the effect of 2 different doses of Trappsol upon change in clinical manifestations of NPC-1 disease

  • Hepatic morphology assessed by qualitative change in ultrasound compared with baseline, NIH total and individual domain severity scores [ Time Frame: Baseline then 14 weeks ]
    To evaluate the effect of 2 different doses of Trappsol upon change in clinical manifestations of NPC-1 disease

  • Number of patients with treatment-related adverse events as graded by CTCAE criteria ( Version 4.03) [ Time Frame: Screening, baseline, days 1, 2-11, weeks 2,4,6,810,12,14 and 18 ]
    Events will be gathered by spontaneous reporting, clinical observation and laboratory tests including auditory tests and auditory evoked potentials to assess hearing


Other Outcome Measures:
  • Hepatic elasticity [ Time Frame: Baseline and 14weeks ]
    To investigate the effect of 2 different doses of intravenous Trappsol upon hepatic elasticity (measured by ultrasound scan) at 14 weeks (after 7 doses) in patients with NPC-1 disease

  • Filipin signal intensity [ Time Frame: Baseline and 12weeks ]
    To investigate the effect of 2 different doses of intravenous Trappsol on filipin signal intensity (measured in cultured fibroblasts collected by skin biopsy) at 14 weeks (after 7 doses) in patients with NPC-1 disease


Estimated Enrollment: 12
Anticipated Study Start Date: April 28, 2017
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Hydroxypropyl-best-cyclodextrin IV 1500 mg/kg
Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
Drug: Hydroxypropyl-beta-cyclodextrin
Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
Other Name: Hydroxypropyl-beta-cyclodextrin (HP-β-CD)
Active Comparator: Hydroxypropyl-best-cyclodextrin IV 2500 mg/kg
Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8h every 2 weeks
Drug: Hydroxypropyl-beta-cyclodextrin
Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
Other Name: Hydroxypropyl-beta-cyclodextrin (HP-β-CD)

Detailed Description:

The planned study has been designed as a Phase I, double-blind, randomised, single-centre, parallel group study based on information and data available from the administration of Trappsol Cyclo via compassionate/named patient use in patients with NPC-1, and data on other cyclodextrin products in the scientific literature.

The study is comprised of a screening phase of up to 4w a treatment phase of 12w and a 4w follow-up The primary objective is to compare the plasma pharmacokinetics of single and multiple doses of two different levels of IV Trappsol Cyclo .Secondary objectives include investigation of the HP-β-CD effect of different doses of IV Trappsol Cyclo upon serum and lymphocytic markers of cholesterol metabolism and evaluation of Trappsol concentrations in the cerebrospinal fluid (CSF) following IV administration , evaluation of the impact of treatment upon measures of neurological function including ataxia, aphasia and saccadic eye movements, and the impact of treatment upon behavioral aspects of NPC-1.

It is planned to recruit a total of 12 patients to the study. Patients will be randomised 1:1 to one of the two dose levels (1500 mg/kg or 2500 mg/kg; six patients per dose level). Treatment will be administered every two weeks by slow IV infusion over 8 hours at different concentrations to achieve the proscribed dose levels. Patients will receive treatment for a total of 12 weeks. Patients who withdraw prior to completion of the initial pharmacokinetic and pharmacodynamic assessments will be replaced.

The design of the proposed study thus enables early assessment of potential biochemical markers of response but allows for a sufficient dosing duration to enable the short-term effectiveness of Trappsol in NPC to be assessed.

The maximum dose proposed for this study is below the maximum dose for which long term clinical data is available in 2 patients (2800 mg/kg weekly for 3-5 years). Although individual clinicians have not always utilized an escalating rate of infusion, the reports of infusion related reactions in three patients suggest that this is an appropriate clinical strategy to mitigate the risk of such events and is consistent with dosing administration for other therapeutic agents. In the proposed study, treatment will be administered less frequently than has been undertaken in compassionate use. This longer dosing interval is supported by nonclinical data comparing the metabolism of cholesterol in non-human species with that in man; although a once weekly dosing interval was initially studied in man based on data in the mouse, HP-β-CD cholesterol metabolism/turnover in the mouse is 13-fold higher than in man which, in NPC, likely translates into a 13-fold slower accumulation of cholesterol in human cells compared with those of the mouse.Therefore, it is theorized that, given the slower cholesterol metabolism in humans, the dosing interval could be much less frequent in man than in mouse; however, based on what is known about cholesterol metabolism in humans and the pharmacokinetic and pharmacodynamic effect of HP-β-CD in the mouse, a dosing interval of 2 weeks in man is likely to be well within the therapeutic dosing interval and also minimizes the amount of infusions required to be administered.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Confirmed diagnosis of NPC-1 defined as one of the following

    1. Two NPC-1 mutations on exome gene sequencing
    2. One NPC-1 mutation and positive filipin staining (current or prior)
    3. Vertical supranuclear gaze palsy [VSGP] plus either ≥ one NPC-1 mutation or positive filipin staining and no NPC-2 mutations
  2. NIH NPC Severity Score <30 and with no more than 4 individual domains with a score ≥ 3.
  3. Age range: 18 years upwards
  4. At least one systemic manifestation of NPC disease defined as one or more of

    1. Clinically detectable hepatomegaly and/or either ALT or AST outside the normal range for the study laboratory
    2. Clinically detectable splenomegaly
    3. Impaired respiratory function due to NPC or a history of pneumonia in the last 12 months
    4. Thrombocytopenia (<150,000/mm3)
  5. Negative urine pregnancy test for females of child bearing potential
  6. Written, informed consent

Exclusion Criteria:

  1. The presence of NPC-2 mutations on exome gene sequencing
  2. Previous receipt of cyclodextrin therapy within 3 months of baseline
  3. Previous receipt of miglustat within 6 months of baseline
  4. Receipt of any of the following medications within 1 month of baseline: Coenzyme Q10, curcumin, cinnamon, fish oil supplements, high dose vitamin D (>500 milli-International unit (mIU)/day), acetyl leucine, or gingko biloba
  5. Concurrent treatment with any therapy indicated for the lowering of cholesterol such as statins, fibrates, ezetimibe
  6. Karnofsky score < 40
  7. Inability to comply with the proposed protocol assessments
  8. Concurrent medical conditions representing a contraindication to any of the study medications
  9. Grade 3 renal impairment or worse as indicated by eGFR< 60mL/min/1.73m2
  10. Clinical evidence of acute liver disease including symptoms of jaundice or right upper quadrant pain or INR >1.8
  11. Involvement in another interventional clinical trial within the previous 6 months from baseline
  12. Weight <40 kg or >100 kg
  13. Male patients and female patients of childbearing potential who are not willing to use appropriate birth control (i.e. double barrier birth control) from enrolment until the follow-up visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02939547

Contacts
Contact: Sharon Hrynkow, PhD sharon.hrynkow@cyclodex.com
Contact: Kristine Nelson, RN 1 301 251 1161 knelson@emmes.com

Locations
United States, California
UCSF Benioff Children's Hospital Oakland Recruiting
Oakland, California, United States, 94609
Contact: Caroline Hastings, MD    510-428-3631    chastings@mail.cho.org   
Contact: Cyrus Bascon    1-510-428-3885 ext 6953    CBascon@mail.cho.org   
Sponsors and Collaborators
CTD Holdings, Inc.
Investigators
Principal Investigator: Caroline Hastings, MD Oakland CA
  More Information

Publications:
Coussement W, Van Cauteren H, Vandenberghe J, et al. Toxicological profile of hydroxypropyl Beta-cyclodextrin (HP-Beta-CD) in laboratory animals. In: Minutes of the Fifth International Symposium on cyclodextrins; 28-30 March 1990; Paris, France: Editions de Santé; 1990 p. 522-4.

Responsible Party: CTD Holdings, Inc.
ClinicalTrials.gov Identifier: NCT02939547     History of Changes
Other Study ID Numbers: CTD-TCNPC-101
Study First Received: September 21, 2016
Last Updated: March 28, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by CTD Holdings, Inc.:
intravenous
cyclodextrin
compassionate
Trappsol

Additional relevant MeSH terms:
Niemann-Pick Diseases
Niemann-Pick Disease, Type A
Niemann-Pick Disease, Type C
Pick Disease of the Brain
Aphasia, Primary Progressive
Frontotemporal Dementia
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Histiocytosis, Non-Langerhans-Cell
Histiocytosis
Lymphatic Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders
Frontotemporal Lobar Degeneration
Dementia
Neurocognitive Disorders
Mental Disorders
Aphasia
Speech Disorders
Language Disorders

ClinicalTrials.gov processed this record on May 23, 2017